Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry

Leukemia

Volumn 29, Issue 9, 2015, Pages 1875-1881

  Bernal, T ^a   Martinez Camblor P ^a,b   Sanchez Garcia J ^c   De Paz, R ^d   Luno E ^a   Nomdedeu, B ^e   Ardanaz, M T ^f   Pedro, C ^g   Amigo, M L ^h   Xicoy, B ⁱ   Del Canizo C ^j   Tormo, M ^k   Bargay, J ^l   Valcarcel D ^m   Brunet, S ⁿ   Benlloch, L ^o   Sanz, G ^p  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL MORALES MESEGUER   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^l HOSPITAL SON LLÀTZER   (Spain)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^o Grupo Español de Síndromes Mielodisplásicos   (Spain)

^p HOSPITAL UNIVERSITARIO LA FE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLOSPORIN; LACTATE DEHYDROGENASE; LENALIDOMIDE; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CHROMOSOME 7; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; DISEASE COURSE; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROGNOSIS; REGISTER; SPAIN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; REGISTRIES; SPAIN; TREATMENT OUTCOME;

EID: 84940791892     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.115     Document Type: Article

References (22)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-1885.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
3. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
4. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
6. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
7. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008.
8. Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res 2009; 127: 1-4.
9. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 1984; 3: 35-44.
10. Arenas-Fernandez J, Fernandez-Martin JL, Cannata-Andia JB, Martinez-Camblor P. [Observational studies: the hazard and other gods]. Med Clin (Barc) 2014; 142: 80-84.
11. Cannata-Andia JB, Fernandez-Martin JL, Locatelli F, London G, Gorriz JL, Floege J et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013; 84: 998-1008.
12. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Statist Assoc 1999; 94: 496-509.
13. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors for response and overall survival in 282 patients with higherrisk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403-411.
14. Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 2013; 40: 666-675.
15. Bally C, Thepot S, Quesnel B, Vey N, Dreyfus F, Fadlallah J et al. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leuk Res 2013; 37: 637-640.
16. Seymour JF, Dohner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al. Azacitidine vesrus conventional care regimens in older patients with newly diagnosed acute myeloid leukemia (430% bone marrow blasts) with morphologic dysplastic changes: a subgroup analysis of the AZA-AML-001 trial. Blood 2014; 124: 10 [abstract].
17. Maynadie M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica 2013; 98: 230-238.
18. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010; 28: 2847-2852.
19. Dinmohamed AG, Visser O, van Norden Y, Huijgens PC, Sonneveld P, van de Loosdrecht AA et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer 2014; 50: 1004-1012.
20. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
21. Stauder R, Nosslinger T, Pfeilstocker M, Sperr WR, Wimazal F, Krieger O et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 2008; 6: 927-934.
22. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223-2231.